Serving 500+ biopharmaceutical companies globally:
Generated: September 22, 2017
|Title:||Gene delivery stent using titanium oxide thin film coating, and method for fabricating same|
|Abstract:||The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells. Accordingly, late thrombosis and metal allergy may be reduced, and vascular restenosis in the stent region may be prevented, thereby making it possible to increase treatment effects of the bare metal stent.|
|Inventor(s):||Kwon; Jin Sook (Gwangju, KR), Ahn; Young Keun (Gwangju, KR), Jeong; Myung Ho (Gwangju, KR), Song; Sun Jung (Gwangju, KR), Cho; Dong Lyun (Gwangju, KR)|
|Assignee:||Chonnam National University Hospital (Gwangju, KR)|
|Patent Claims:||1. A method for fabricating a gene delivery stent using titanium oxide thin film coating, the method comprising: a) a titanium oxide coating step of coating a surface
of a metal stent with a titanium oxide thin film consisting of titanium oxide (TiO.sub.2), TiO.sub.2-xN.sub.x wherein 0.001<x<1, or a mixture thereof; b) a surface modifying step of modifying the surface of the coated titanium oxide thin film to
introduce a hydroxyl group; c) a drug adhering step of adhering drugs onto the titanium oxide thin film surface-modified by binding a functional group of the drug to the hydroxyl group of the titanium oxide thin film to form a drug layer; and d) an
oligonucleotide adhering step of adhering oligonucleotide onto the drug layer by binding oligonucleotide to the drug to form an oligonucleotide layer wherein in step b), the surface of the titanium oxide thin film is modified for 10 minutes to 2 hours by
transferring water vapor, or oxygen and hydrogen into a plasma vacuum chamber and generating non-thermal plasma, and wherein applied discharge power is in the range of 20-50 W, wherein in step b), when water vapor is used, the water vapor is transferred
from an external introduction tube connected to the plasma vacuum chamber into the plasma vacuum chamber at a reduced pressure of 1.times.10.sup.-3 to 1 torr, wherein in step a) the titanium oxide thin film is coated onto the surface of the metal stent
for 1 to 6 hours by transferring a titanium precursor, carrier gas, and reaction gas and generating plasma in a plasma vacuum chamber, wherein the carrier as is at least one selected from the group consisting of nitro en argon, and helium, wherein the
reaction gas is at least one selected from the group consisting of water vapor, ozone, and oxygen, and wherein as the drug in step c), at least one of abciximab, alpha lipoic acid, and heparin is selected to thereby be adhered.
2. The method of claim 1, wherein the metal stent is made of stainless steel, nitinol, tantalum, platinum, titanium, cobalt, chromium, a cobalt-chromium alloy, or a cobalt-chromium-molybdenum alloy.
3. The method of claim 1, wherein the titanium precursor is at least one selected from a group consisting of titanium butoxide, tetra-ethyl-methyl-amino-titanium, titanium ethoxide, titanium isopropoxide, and tetra-methyl-hepta-diene-titanium.
4. The method of claim 1, wherein the oligonucleotide in step d) is selected from a group consisting of gDNA, cDNA, pDNA, mRNA, tRNA, rRNA, siRNA, miRNA, and antisense-oligonucleotide.
5. The method of claim 1, wherein in the oligonucleotide adhering step (step d), a functional group of the oligonucleotide is adhered to the functional group of the drug by at least one bond of a hydrogen bond, a dipole-dipole bond, an induced dipole bond, and a disulfide bond (S--S bond) therebetween.
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|South Korea||10-2010-0127251||Dec 13, 2010|
|South Korea||10-2011-0121949||Nov 22, 2011|
|PCT Filed||December 02, 2011||PCT Application Number:||PCT/KR2011/009298|
|PCT Publication Date:||June 21, 2012||PCT Publication Number:||WO2012/081850|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Inventors||Patent Expiration||Status||Orphan||Source|
|INJECTABLE; INJECTION||103575||001||1994-12-22||► Subscribe||Chonnam National University Hospital (Gwangju, KR)||Kwon; Jin Sook (Gwangju, KR), Ahn; Young Keun (Gwangju, KR), Jeong; Myung Ho (Gwangju, KR), Song; Sun Jung (Gwangju, KR), Cho; Dong Lyun (Gwangju, KR)||► Subscribe||RX||search|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.